Treatment With Adalimumab 80 mg Every Other Week in Inflammatory Bowel Disease: Results of Treatment Intensification in Clinical Practice

BACKGROUND: Loss of response to anti-tumor necrosis factor drugs in patients with inflammatory bowel disease (IBD) is frequent and, in case of low drug levels, treatment intensification is recommended. In addition, in cases in which clinical response without attainment of remission (clinical, endosc...

Descripción completa

Detalles Bibliográficos
Autores principales: Calvo Moya, Marta, González Lama, Yago, Ruíz Antorán, Belén, Omella Usieto, Ignacio, el Hajra Martinez, Ismael, Santos Pérez, Elena, Menchén Viso, Belén, Matallana Royo, Virginia, González Partida, Irene, de Lucas Tellez de Meneses, Rocío, Bella Castillo, Pablo, González Rodriguez, Macarena, Vera Mendoza, María Isabel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Observations and Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9922047/
https://www.ncbi.nlm.nih.gov/pubmed/36785555
http://dx.doi.org/10.1093/crocol/otac051

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9922047/
https://www.ncbi.nlm.nih.gov/pubmed/36785555
http://dx.doi.org/10.1093/crocol/otac051

Ejemplares similares